253 related articles for article (PubMed ID: 34333394)
21. Recent advances in the discovery of small molecule c-Met Kinase inhibitors.
Parikh PK; Ghate MD
Eur J Med Chem; 2018 Jan; 143():1103-1138. PubMed ID: 29157685
[TBL] [Abstract][Full Text] [Related]
22. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
23. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
Nan X; Li HJ; Fang SB; Li QY; Wu YC
Eur J Med Chem; 2020 May; 193():112241. PubMed ID: 32200199
[TBL] [Abstract][Full Text] [Related]
24. In silico design, synthesis and activity of potential drug-like chrysin scaffold-derived selective EGFR inhibitors as anticancer agents.
Debnath S; Kanakaraju M; Islam M; Yeeravalli R; Sen D; Das A
Comput Biol Chem; 2019 Dec; 83():107156. PubMed ID: 31710991
[TBL] [Abstract][Full Text] [Related]
25. Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma.
Soodgupta D; Pan D; Cui G; Senpan A; Yang X; Lu L; Weilbaecher KN; Prochownik EV; Lanza GM; Tomasson MH
Mol Cancer Ther; 2015 Jun; 14(6):1286-1294. PubMed ID: 25824336
[TBL] [Abstract][Full Text] [Related]
26. Targeting MYC: From understanding its biology to drug discovery.
Ross J; Miron CE; Plescia J; Laplante P; McBride K; Moitessier N; Möröy T
Eur J Med Chem; 2021 Mar; 213():113137. PubMed ID: 33460833
[TBL] [Abstract][Full Text] [Related]
27. A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation.
Castell A; Yan Q; Fawkner K; Hydbring P; Zhang F; Verschut V; Franco M; Zakaria SM; Bazzar W; Goodwin J; Zinzalla G; Larsson LG
Sci Rep; 2018 Jul; 8(1):10064. PubMed ID: 29968736
[TBL] [Abstract][Full Text] [Related]
28. Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors.
Lin TE; Sung LC; Chao MW; Li M; Zheng JH; Sung TY; Hsieh JH; Yang CR; Lee HY; Cho EC; Hsu KC
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):226-235. PubMed ID: 34894949
[TBL] [Abstract][Full Text] [Related]
29. Inhibiting Eukaryotic Elongation Factor 2 Kinase: An Update on Pharmacological Small-Molecule Compounds in Cancer.
Zhu S; Liao M; Tan H; Zhu L; Chen Y; He G; Liu B
J Med Chem; 2021 Jul; 64(13):8870-8883. PubMed ID: 34162208
[TBL] [Abstract][Full Text] [Related]
30. Targeted Disruption of Myc-Max Oncoprotein Complex by a Small Molecule.
Choi SH; Mahankali M; Lee SJ; Hull M; Petrassi HM; Chatterjee AK; Schultz PG; Jones KA; Shen W
ACS Chem Biol; 2017 Nov; 12(11):2715-2719. PubMed ID: 28976731
[TBL] [Abstract][Full Text] [Related]
31. Free energy perturbation guided Synthesis with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
Karnik KS; Sarkate AP; Tiwari SV; Azad R; Wakte PS
Bioorg Chem; 2021 Oct; 115():105226. PubMed ID: 34364055
[TBL] [Abstract][Full Text] [Related]
32. MKK3 as oncotarget.
Bossi G
Aging (Albany NY); 2016 Jan; 8(1):1-2. PubMed ID: 26805700
[No Abstract] [Full Text] [Related]
33. Developing Antagonists for the Met-HGF/SF Protein-Protein Interaction Using a Fragment-Based Approach.
Winter A; Sigurdardottir AG; DiCara D; Valenti G; Blundell TL; Gherardi E
Mol Cancer Ther; 2016 Jan; 15(1):3-14. PubMed ID: 26712116
[TBL] [Abstract][Full Text] [Related]
34. Computational study on natural compounds inhibitor of c-Myc.
Ren J; Huangfu Y; Ge J; Wu B; Li W; Wang X; Zhao L
Medicine (Baltimore); 2020 Dec; 99(50):e23342. PubMed ID: 33327259
[TBL] [Abstract][Full Text] [Related]
35. Dual Bcl-X
Daguer JP; Gonse A; Shchukin Y; Farrera-Soler L; Barluenga S; Winssinger N
Bioorg Med Chem; 2021 Aug; 44():116282. PubMed ID: 34216984
[TBL] [Abstract][Full Text] [Related]
36. Targeting MKK3 as a novel anticancer strategy: molecular mechanisms and therapeutical implications.
Baldari S; Ubertini V; Garufi A; D'Orazi G; Bossi G
Cell Death Dis; 2015 Jan; 6(1):e1621. PubMed ID: 25633290
[TBL] [Abstract][Full Text] [Related]
37. Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy.
Alsfouk A
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):693-706. PubMed ID: 33632038
[TBL] [Abstract][Full Text] [Related]
38. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
Davis GD; Vasanthi AH
Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
[TBL] [Abstract][Full Text] [Related]
39. Discovery of First-in-Class TAK1-MKK3 Protein-Protein Interaction (PPI) Inhibitor
Tang ML; Li H; Ning JF; Shen X; Sun X
J Med Chem; 2022 May; 65(9):6690-6709. PubMed ID: 35442672
[TBL] [Abstract][Full Text] [Related]
40. Identification of potent Yes1 kinase inhibitors using a library screening approach.
Patel PR; Sun H; Li SQ; Shen M; Khan J; Thomas CJ; Davis MI
Bioorg Med Chem Lett; 2013 Aug; 23(15):4398-403. PubMed ID: 23787099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
